• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    For Immediate Release:
    January 13, 2022

    Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. 

    Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.

    “Treatment options for cats with osteoarthritis are very limited. Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats. But with longer lives come chronic diseases, such as osteoarthritis,” said Steven M. Solomon, M.P.H., D.V.M., director of the FDA’s Center for Veterinary Medicine. “Today’s approval marks the first treatment option to help provide relief to cats that are suffering from this condition and may significantly improve their quality of life. We also hope that today’s approval of the first monoclonal antibody by the FDA for any animal species will expand research and development of other monoclonal antibody products to treat animal diseases.” 

    Osteoarthritis is a degenerative condition of the joints in which the normal cartilage cushion in the joints breaks down. Eventually, the bones in the joint rub against each other, causing pain, decreased joint movement, and sometimes the formation of bone spurs or other changes in and around the joint. Osteoarthritis continues to get worse over time; however, Solensia can help manage the pain associated with the condition to improve the cat’s quality of life.

    Solensia is available only by prescription from a licensed veterinarian because professional expertise is required to properly diagnose pain associated with osteoarthritis in cats, administer the injection and monitor the safe use of the product, including treatment of any adverse reactions. Solensia is given through subcutaneous (under the skin) injection once a month and is dosed based on the weight of the animal. 

    Because of the difficulty in assessing chronic pain levels in cats, the FDA looked at whether the overall evidence supported the conclusion that Solensia was effective in controlling pain associated with osteoarthritis in cats. The effectiveness of Solensia was evaluated in two effectiveness studies using three clinical assessments that measured different aspects of pain associated with osteoarthritis in cats. 

    The two clinical trials were both masked, randomized, controlled field studies involving client-owned cats with clinical signs of osteoarthritis. The cats’ veterinarians assessed the cats based on orthopedic examinations before and after treatment. The owners of the cats provided baseline scores of their cats’ levels of impairment doing certain activities (such as jumping onto furniture, using the litter box or grooming), compared to the cats’ level of ability before they developed osteoarthritis. The owners then assessed their cats’ response after receiving treatment. Overall, the cats in the treatment group had better assessment scores than those in the control group.

    The most common side effects seen in cats treated with Solensia included vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itchy skin). These effects were relatively mild and did not require cessation of treatment. 

    Veterinarians should advise owners about the possible adverse events and side effects before using the drug. The FDA encourages cat owners to work with their veterinary team to report any adverse events or side effects potentially related to the use of any drug, including Solensia.

    The FDA granted approval of Solensia to Zoetis Inc.
     

    Related Information

    Related Information
    • NADA 141-546 FOI Summary (fda.gov)

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Veronika Pfaeffle
    301-310-2576
    Consumer:
    888-INFO-FDA

    Get the next $ZTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    1/12/2024$195.00 → $215.00Buy
    Stifel
    12/19/2023$230.00Buy
    Jefferies
    12/7/2023$237.00Outperform
    Exane BNP Paribas
    9/6/2023$230.00Buy
    HSBC Securities
    7/12/2022$205.00Overweight
    Piper Sandler
    3/9/2022$232.00 → $208.00Neutral
    Citigroup
    More analyst ratings

    $ZTS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Zoetis Inc.

      10-Q - Zoetis Inc. (0001555280) (Filer)

      5/6/25 1:29:54 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zoetis Inc. (0001555280) (Filer)

      5/6/25 7:03:35 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Zoetis Inc.

      DEFA14A - Zoetis Inc. (0001555280) (Filer)

      4/9/25 9:04:50 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

      For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

      1/13/22 10:26:13 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Executive Vice President Polzer Robert J

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:24 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Sarbaugh Keith

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:13 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Vice President Fuller Julie

      4 - Zoetis Inc. (0001555280) (Issuer)

      4/7/25 4:55:03 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Financials

    Live finance-specific insights

    See more

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Reports Fourth Quarter and Full Year 2024 Results

      Reports Revenue of $2.3 Billion, Growing 5%, and Net Income of $581 Million, or $1.29 per Diluted Share, Increasing 11% and 13%, Respectively, on a Reported Basis for Fourth Quarter 2024 Delivers 6% Operational Growth in Revenue and 9% Operational Growth in Adjusted Net Income for Fourth Quarter 2024 Delivers 9% Organic Operational Growth in Revenue for Fourth Quarter 2024 After Accounting for the Divestiture of the Medicated Feed Additive Product Portfolio, Certain Water Soluble Products and Related Assets Reports Adjusted Net Income of $632 Million, or Adjusted Diluted EPS of $1.40, for Fourth Quarter 2024 Reports Revenue of $9.3 Billion, Growing 8%, and Net Income of $2.5

      2/13/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Zoetis with a new price target

      Leerink Partners initiated coverage of Zoetis with a rating of Outperform and set a new price target of $215.00

      12/2/24 7:04:18 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Zoetis with a new price target

      BTIG Research initiated coverage of Zoetis with a rating of Buy and set a new price target of $220.00

      7/25/24 6:48:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Zoetis with a new price target

      Stifel reiterated coverage of Zoetis with a rating of Buy and set a new price target of $215.00 from $195.00 previously

      1/12/24 8:18:04 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Announces First Quarter 2025 Results

      Reports Revenue of $2.2 Billion, Growing 1%, and Net Income of $631 Million, or $1.41 per Diluted Share, Increasing 5% and 8%, Respectively, on a Reported Basis for First Quarter 2025 Delivers 9% Organic Operational Growth in Revenue and 6% Organic Operational Growth in Adjusted Net Income for First Quarter 2025 Reports Adjusted Net Income of $662 Million, or Adjusted Diluted EPS of $1.48, for First Quarter 2025 Updates Full Year 2025 Revenue Guidance to $9.425 - $9.575 Billion to Reflect the Impact of Foreign Exchange and Maintains Guidance for Organic Operational Revenue Growth of 6% to 8% Updates Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income t

      5/6/25 7:00:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

      Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2025. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nu

      3/27/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis to Participate in Upcoming Investor Conferences

      Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET. Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET. Investors and other interested parties can access live audio webcasts of the presentations by visiting http://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind b

      2/20/25 8:30:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/13/24 5:17:36 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      1/26/24 11:49:41 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

      SC 13G/A - Zoetis Inc. (0001555280) (Subject)

      2/9/23 11:37:19 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

      New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu

      11/11/24 9:20:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

      Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand

      4/1/24 4:30:00 PM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Petco Love Announces Newest Board Members

      Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world

      11/14/23 6:03:00 AM ET
      $ZTS
      Biotechnology: Pharmaceutical Preparations
      Health Care